Status:

UNKNOWN

The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass

Lead Sponsor:

Imam Khomeini Hospital

Collaborating Sponsors:

Tehran University of Medical Sciences

Conditions:

Chronic Kidney Disease stage3

Chronic Kidney Disease stage4

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

PHASE3

Brief Summary

Coronary artery disease is a major cause of death in patients with renal dysfunction Among patients who undergo coronary artery bypass grafting ,renal dysfunction is known To be a major predictor of i...

Eligibility Criteria

Inclusion

  • 80\<age\>18
  • ckd patients with stage 3,4
  • CABG for the first time

Exclusion

  • age\<18
  • previous CABG (coronary artery bypass grafting)
  • AKI(acute kidney injury)
  • dialysis patients

Key Trial Info

Start Date :

August 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2013

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT01410617

Start Date

August 1 2011

End Date

December 1 2013

Last Update

March 27 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tehran Herat Center

Tehran, Tehran Province, Iran, 1411713131

The Effect of Prophylactic Hemodialysis on the Morbidity and Mortality of the Patients With Chronic Kidney Disease Stages 3-4 Undergoing Coronary Artery Graft Bypass | DecenTrialz